PharmaCyte Biotech to Hold Shareholder Call
January 18 2017 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that Chief Executive
Officer Kenneth L. Waggoner will conduct a shareholder conference
call at 4:30 p.m. EST on Tuesday, February 7, 2017.
Commenting on the upcoming shareholder
conference call, Mr. Waggoner said, “After what can only be
described as a landmark moment in PharmaCyte’s history, we are
excited to report on what was a positive pre-IND meeting with the
U.S. FDA. We made excellent progress and received good advice and
guidance toward the goal of filing our IND. We now have a clear
path forward, and we will use this upcoming shareholder call to lay
out that path for analysts, shareholders and the public.”
Management will provide the latest information
to analysts and shareholders about PharmaCyte's upcoming clinical
trial in locally advanced, inoperable pancreatic cancer (LAPC), the
company’s interaction with the U.S. Food and Drug Administration
(FDA) and respond to written questions. Analysts and shareholders
are requested to submit questions they may have about PharmaCyte’s
clinical development program via email to
investorrelations@pharmacyte.com. Mr. Waggoner will respond to as
many of the questions as possible in the time permitted for the
call.
Date: |
February 7, 2017 |
Time: |
4:30 p.m. EST |
Telephone Number: |
(515) 739-1030 |
Access Code: |
915-603-449 |
Once the call has been completed, an audio
replay will be available to the public. PharmaCyte will provide a
telephone number and access code to listen to the recorded
call.
About PharmaCyte
BiotechPharmaCyte Biotech is a clinical stage
biotechnology company developing therapies for cancer and diabetes
based upon a proprietary cellulose-based live cell encapsulation
technology known as “Cell-in-a-Box®”. This technology will be used
as a platform upon which therapies for several types of cancer and
diabetes are being developed. PharmaCyte’s therapy for cancer
involves encapsulating genetically engineered human cells that
convert an inactive chemotherapy drug into its active or
“cancer-killing” form. These encapsulated cells are implanted as
close to the patient’s cancerous tumor as possible. Once
implanted, a chemotherapy drug that is normally activated in the
liver (ifosfamide) is given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been implanted. When the ifosfamide
comes in contact with the encapsulated cells they act as an
artificial liver and activate the chemotherapy drug at the source
of the cancer. This “targeted chemotherapy” has proven effective
and safe to use in past clinical trials and results in no side
effects.
In addition to developing a novel therapy for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient they will function as a
“bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking
statements regarding PharmaCyte and its future events and results
that involve inherent risks and uncertainties. The words
"anticipate", "believe", "estimate", "expect", "intend", "plan" and
similar expressions, as they relate to PharmaCyte or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte, could cause actual results to differ materially from
those set forth in the forward-looking statements. They include
PharmaCyte's ability to continue as a going concern, delays or
unsuccessful results in preclinical studies and clinical trials,
flaws or defects regarding its product candidates, changes in
relevant legislation or regulatory requirements, uncertainty of
protection of PharmaCyte’s intellectual property and PharmaCyte’s
continued ability to raise capital. PharmaCyte does not assume any
obligation to update any of these forward-looking
statements.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com